Global Non-Invasive Cancer Diagnostics Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Therapeutics, Techniques & Region – Industry Forecasts (2024 to 2029)

Updated On: January, 2024
ID: 5357
Pages: 175

Non-Invasive Cancer Diagnostics Market Size (2023 to 2028)

The global non-invasive cancer diagnostics market size is expected to reach USD 201.02 billion by 2027 from USD 141.99 billion in 2023, to grow at a CAGR of 7.2% from 2023 to 2028.

Cancer is a complicated medical disorder for which no effective remedy has yet been established. Non-invasive cancer diagnostics can be defined as a procedure for identifying cancer problems with little body incision. Cancer is a disease caused by a genetic change in the cells, resulting in uncontrolled growth and the formation of a tumor-like structure. Imaging is the preferred method of cancer detection, but it does not provide for genetic access; conversely, biopsies that allow for genetic access are complex and difficult to do repeatedly during cancer diagnosis and therapy. Because of the rise in the occurrence of chronic cancers such as breast cancer and lung cancer, non-invasive cancer diagnostics are becoming more important than traditional diagnosis.

According to the World Health Organization and the World Cancer Survey, by 2020, there will be roughly 15 million new cancer cases each year, with breast, ovarian, and gastrointestinal cancers being the most common. Due to the traumatic experience and inefficiency of existing procedures, new non-invasive cancer diagnostics have gained appeal, with advanced approaches such as liquid biopsy outperforming previous restrictions and detecting rare cells and biomarkers such as CTCs, DNA/RNA (ctNAs), and exosomes. The market for non-invasive cancer diagnostics and technologies is dominated by breast cancer. Skin cancer, for particular, is the most frequent type of cancer and requires early diagnosis and treatment. Non-invasive imaging technologies help clinicians in diagnosing skin cancers and lowering patient morbidity and death. Breast, lung, blood, and other cancers are detected using non-invasive cancer diagnosis technologies.


The primary drivers for the global noninvasive cancer diagnostics and technologies market include rising cancer prevalence, an aging population, rising obesity, escalating demand for noninvasive cancer diagnostic technologies, expanding awareness among people about cancer and its treatment, and expanding research and development activities in cancer diagnostic and treatment technologies. Methods such as identifying genetic structure, biomarkers, and changes in molecular biology and imaging technology are used in non-invasive cancer diagnosis. During the forecast period, the increasing need for accurate and less invasive diagnostic increased healthcare spending drives the market growth.

Rapid technological advancements and device innovation are expected to generate lucrative expansion opportunities. In the coming years, market growth is further predicted to be driven by increased government initiatives to improve healthcare diagnostic and technology. Furthermore, developing economies such as China and India, which are seeing an increase in medical tourism, helps the market expansion. People are more aware of the benefits of early cancer detection and treatment, which has increased the number of people getting a diagnosis.


The global non-invasive cancer diagnostics market is restrained by high treatment costs and strict regulatory rules. The non-invasive cancer diagnostics market in undeveloped and emerging nations is hesitant to adopt these high-cost devices, posing a challenge to the market. The development of an effective diagnostic with appropriate sensitivity and specificity for the early diagnosis of lung cancer, particularly the detection of circulating tumor DNA present in smaller amounts, poses considerable challenges.

Impact of COVID-19 on the global non-invasive cancer diagnostics market:

The World Health Organization announced the COVID-19 as a pandemic and emergence of healthcare. All the countries have imposed a lockdown and ban on flights to stop the widespread of the coronavirus. It has negatively affected all sectors of the economy except in the case of the pharmaceutical sector. The non-invasive diagnostics market had experienced a downfall in the pandemic's initial period as all the activities were either canceled or postponed. The nation's focus was shifted to fight against the coronavirus. The investment and funding of non-invasive diagnostics were diverted, and cancer research institutes and hospitals were used as coronavirus treating centers. The covid-19 has positively affected the non-invasive market during the last months of 2020. Despite the situations imposed by the COVID-19, the global non-invasive cancer diagnostics market is still believed to come out from the negative impact at the earliest and expected to show healthy growth during the forecast period.




Market Size Available

2022 to 2028

Base Year


Forecast Period

2023 to 2028

Segments Covered

By Therapeutics, Techniques, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa


This research report on the global non-invasive cancer diagnostics market has been segmented and sub-segmented into the following categories and analyzed market size and forecast until 2027.

Non-Invasive Cancer Diagnostics Market - By Therapeutics:

  • Blood cancer
  • Breast Cancer
  • Lung Cancer
  • Solid Tumors

Based on therapeutics, the breast cancer segment had recorded the majority share in the recent past and predicted to continue the domination throughout the forecast period. Factors such as a rapid increase in the number of breast cancer cases worldwide and improving the healthcare sector are majorly promoting the segment.

Non-Invasive Cancer Diagnostics Market - By Techniques:

  • Immunochemistry
  • Clinical Chemistry
  • Molecular Diagnostics

Clinical chemistry is expected to hold a leading share in the global non-invasive cancer diagnostics market based on the techniques. The availability of successful clinical data for several cancer indications and other non-invasive diagnostic technologies propels the market growth. However, it is expected to replace the existing invasive diagnostic tools in the coming years. 

Non-Invasive Cancer Diagnostics Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Geographically, the North American market is estimated to be dominating the global non-invasive cancer diagnostic market during the forecast period due to the increasing healthcare expenditure and research & development activities, and Y-O-Y growth in the number of breast cancer cases. 

The European market had accounted second-largest share in the global market in 2020 and is predicted to register a healthy growth rate during the forecast period due to increasing government initiatives towards efficient cancer diagnosis, availability of advanced technologies, and awareness in the people regarding a cancer diagnosis.

The Asia Pacific market is anticipated to witness the fastest growth rate during the forecast period. An increase in cancer patients' prevalence and raising awareness among the people about the minimal invasive equipment for the diagnosis will drive the market in this region.


Notable companies operating in the global non-invasive cancer diagnostics market profiled in the report are Precision Therapeutics, Laboratory Corporation of America Holdings (LabCorp), BIOVIEW Inc., Affymetrix Inc., AVIVA Biosciences Corporation, A&G Pharmaceutical, Quest Diagnostics Incorporated, Cancer Genetics Inc., Digene Corporation and Gen-Probe Incorporated.


  • Roche Diagnostics introduced the first in vitro diagnostic immunohistochemistry (IHC) assay in 2019 to improve lung cancer diagnosis.
  • In 2014, the U.S. The FDA approved the product for non-invasive colorectal cancer testing, which is one of the most common cancers seen in recent years.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample